STAAR SURGICAL CO 8-K

What Happened
STAAR Surgical Company announced under Item 5.02 that Nathaniel Sisitsky, the Company's Chief Legal Officer and Corporate Secretary, was terminated effective February 4, 2026. The termination is treated as a company-initiated, without-cause separation. STAAR also entered a consulting agreement with Mr. Sisitsky, effective February 4, 2026, for transition services through March 13, 2026 (or earlier by agreement).

Key Details

• Separation Date: February 4, 2026; termination treated as without cause.
• Severance: Eligible for 12 months of base pay and 12 months of company-paid insurance premium reimbursements, per his December 12, 2023 severance agreement, subject to execution and nonrevocation of a general release.
• Cash payments: Entitled to his 2025 annual bonus on the same basis/timing as other executives and the remaining unpaid cash recognition/retention installment of $75,000.
• Equity and consulting pay: March 2026 RSUs were accelerated and vested as of the Separation Date; all other unvested equity (stock options, unvested PSUs, and other RSUs) were forfeited for no consideration. Consulting fees are $8,000 per week, plus a possible $10,000 completion fee if the Company deems the services successfully completed.

Why It Matters
This filing documents an executive change with defined near-term cash and equity consequences: STAAR may incur severance cash payments and accelerated equity vesting (a potential one-time expense), while forfeiture of other awards reduces future equity dilution for the company. The consulting arrangement is intended to support legal transition and continuity. Investors should note these are contractual, disclosed obligations (no speculation on future hires or legal outcomes).